推进深度学习驱动的阿尔茨海默病生成对抗网络的诊断性能和临床适用性
Changxing Qu1,2, Yinxi Zou3, Qingyi Dai2
1Huaxi MR Research Center (HMRRC), Department of Radiology, West China Hospital of Sichuan University, Chengdu 610044, China.
Psychoradiology
|April 26, 2024
概括
生成对抗网络 (GAN) 在诊断阿尔茨海默病 (AD) 和改善医疗图像处理方面表现出更高的准确性. 未来的研究应该涉及临床医生进行验证和增强临床适用性.
科学领域:
- 神经科学是一个神经科学.
- 人工智能的人工智能
- 医疗成像医学成像
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,影响老年人的日常生活,需要早期诊断.
- 生成对抗网络 (GANs) 是一种深度学习技术,在图像处理方面表现出色,但它们在AD诊断中的实用性需要验证.
研究的目的:
- 对阿尔茨海默病诊断中GAN应用的心理放射学研究进行系统审查.
- 将GAN与AD状态分类和AD相关图像处理的现有方法进行比较.
- 评估研究方法和提供临床应用见解.
主要方法:
- 系统审查使用GAN用于阿尔茨海默病诊断的心理放射学研究.
- 对GAN性能与AD分类和图像处理任务中的其他方法进行比较分析.
- 评估研究方法,包括数据源和验证过程.
主要成果:
- 与其他方法相比,GAN在分类阿尔茨海默氏症疾病状态方面表现出卓越的准确性.
- 在与AD相关的图像处理任务中,GAN表现出更高的性能,例如无声化和细分.
- 许多审查的研究依赖于公共数据集,缺乏临床验证和临床医生参与评估.
结论:
- 在阿尔茨海默病的诊断和图像处理中,GANs具有确定的应用价值.
- 临床验证和临床医生专业知识的整合对于改善GAN模型概括和临床实用性至关重要.
- 未来的研究应该专注于人工智能开发人员和临床医生之间的协作努力,以优化AD诊断的GAN.
关键词:
阿尔茨海默病 (AD) 是一种疾病.这是分类分类的分类.计算心理辐射学深度学习是一种深度学习.生成式对抗网络 (GAN) 是一种产生式对抗网络.磁共振成像 (MRI) 的使用.轻度认知障碍 (MCI) 是一种轻度认知障碍.定子发射断层扫描 (PET) 是一种更多相关视频
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
826
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
26.8K
相关概念视频
Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
